Prospects Fund
Prospects Oncology Fund
FACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Ontario First Investment Strategy and have the potential to act as deal flow for the Compass Rose Fund. Prospects funding ranges between $50,000 and $200,000.
Funding is governed by a research contract which grants certain rights to FACIT. FACIT receives no financial consideration on Prospects awards of $50,000 or less (***new limit as of September 2019***). On all other awards, FACIT receives an option to make an investment at the Compass Rose level and act as the agent for commercialization, if mutually agreed. If the option is exercised, funding received from the Prospects Fund will be credited towards FACIT's Compass Rose investment.
How to apply:
The Prospects Fund is accepting pre-submission forms twice yearly on the following dates:
- March 31
- September 30
The pre-submission form can be downloaded here.
Late applications will not be considered.
Selected applicants will then be invited to prepare a Prospects funding application which is subject to due diligence by FACIT.
Select Prospects Funded Projects
Prospects Fund (Other)
Development of WD40 Repeat Domain (WDR) Platform
OICR is developing a programme targeting multiple members of the WD40 repeat domain (WDR) family with small molecules.
Split Intein-Mediated Protein Ligation (SIMPL): a unique and disruptive system for detecting PPIs in real time
Development of a novel system to trap weak or transient protein-protein interactions (PPIs), unique for its tolerance for multiple experimental conditions and utility for drug discovery application
A radially expandable access port to maximize the potential of laparoscopic surgical oncology
Recognizing a real unmet need, Xpan is developing expandable surgical access ports that aim to increase safety and efficiency of minimally invasive surgeries.
A novel platform technology that simultaneously detects solid tumours using MRI and sensitizes cancer cells for maximized radiation therapy performance
Nanology Labs has developed a low toxicity MRI contrast agent which circumvents limitations of other agents currently available.
